Roche's PD-L1 monoanti-Tecentriq shows hope in early triple-negative breast cancer
-
Last Update: 2020-07-14
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Roche's PD-L1 monoantitic Tecentriq (atezolizumab) has been used in conjunction with chemotherapy to improve the treatment of patients with early triple-negativebreast cancer(TNBC), offering new hope for the treatment of the diseaseThe IMpassion031 Phase III study compared Tecentriq/chemotherapy with placebo/chemotherapyThe results showed that Tecentriq/chemotherapy reached the primary endpoint of the experiment: regardless of PD-L1 expression level, it achieved a significant statistical significance and clinical significant improvement in pathology total remission (pCR)"Triple-negative breast cancer is still an invasive disease with a high recurrence rate," said Levi Garraway, chief medical officer atRocheThe goal of treating TNBC early is to provide people with the best chance of healingin this study, not related to the expression of PD-L1, was lower in patients treated with the Tecentriq combination as a new auxiliary therapy (preoperative) for evidence of tumor tissue (pCR) at surgeryTecentriq joint nab-yew alcohol is currently approved in more than 70 countries, including the United States and Europe, for the treatment of tumor expression PD-L1 (IC-1%) of non-removable local late or metastatic TNBC adult patientsThe IMpassion031 data will be discussed with global health authorities, including the Us Food and Drugadministration, theAgency and the European Medicines Agency, to expand the scope of the drug
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
